evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

100 questions · 100 findings · 41 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 31 · 31%GRADE not reported 4 · 4%Very low 34 · 34%Low 19 · 19%Moderate 10 · 10%High 2 · 2%

Intervention not reported

Serious adverse events (number) · people with acute pancreatitis
1 finding from 1 review

Enhanced recovery protocol vs usual care

Serious adverse events (number) · people with major upper gastrointestinal, liver and pancreatic surgery

It is very uncertain whether enhanced recovery protocol changes serious adverse events (number) compared with standard care (very low certainty).

1 finding from 1 review

Anti‐TNF discontinuation vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Anti‐TNF dose reduction vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in number of serious adverse events compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Chondroitin vs placebo

Number of serious adverse events · patients with osteoarthritis

Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review